

**GOVERNMENT OF PAKISTAN
THE PATENT OFFICE**

2nd Floor, Kandawala Building,
M.A. Jinnah Road,
Karachi

No.2/2/2003-F.Sec.

Dated: 02-4-2008

To,

The Manager,
Printing Corporation of Pakistan Press,
University Road,
Karachi

Subject: **WEEKLY NOTIFICATION OF PATENT OFFICE FOR THE
WEEKENDING 16-2-2008 TO BE PUBLISHED ON 03-4-2008 IN
THE GAZETTE OF PAKISTAN PART-V.**

A manuscript copy of the weekly notification regarding application filed application accepted and scaling fee due etc., is forwarded herewith to be published in the next issue of the Gazette of Pakistan Part-V without fail.

(Mrs. Yasmeen Abbasi)
Controller of Patents
Ph: 9215488

ENCL:

NEW APPLICATIONS FOR THE PATENTS

The dates shown in the crescent brackets are the dates claimed under section 86 of the Patents Ordinance 2000.

	<u>11-2-2008</u>	
129/2008	1. Schering Corporation, 2. Pharmacoepia Inc. USA (Priority 13-2-07 USA)	“Functionally selective alpha2c adrenoreceptor agonists”
130/2008	1. Schering Corporation, 2. Pharmacoepia Inc. USA (Priority 13-2-07 USA)	“Functionally selective alpha2c adrenoreceptor agonists”
131/2008	Schering Corporation, USA (Priority 13-2-07 USA)	“Functionally selective alpha2c adrenoreceptor agonists”
132/2008	1. Schering Corporation, USA (Priority 13-2-07 USA)	“Functionally selective alpha2c adrenoreceptor agonists”
133/2008	Schering Corporation, USA (Priority 13-2-07 USA)	“alpha2c adrenoreceptor agonists”
134/2008	IHI Corporation, Japan (Priority 01-3-07 Japan)	“Fluidized bed gasification method”
135/2008	IHI Corporation, Japan (Priority 14-3-07 Japan)	“Fluidized bed gasification system”
136/2008	Indiana University Research &Technology Corporation, USA (Priority 15-2-07 USA)	“Glucagon/glp-1 receptor co-agonists”
137/2008	1. Muhammad Qasim Siddiqui, 2. Muhammad Javaid Mughal 3. Muhammad Naeem and 4. Muhammad Aleem Ahmed PCSIR, Laboratories Karachi, Pakistan	“Automatic foaming ability tester for textile industry”

138/2008	Laboratorios Ammirall, S.A. Spain (Priority 21-2-07 US)	“Novel methods”
139/2008	Sanofi- Aventis France (Priority 23-2-07 France)	“Amorphous solid solution containing a pyrazole-3-carboxamide derivative in amorphous and stabilizing excipients”
	<u>12-2-2008</u>	
140/2008	Janssen Pharmaceutica N.V. Belgium (Priority 13-2-07 Europe)	“Fast-dissociating dopamine 2 receptor antagonists”
141/2008	Janssen Pharmaceutica N.V. Belgium (Priority 14-2-07 US)	“LTA4 H Modulators and uses thereof”
142/2008	Janssen Pharmaceutica N.V. Belgium (Priority 14-2-07 US)	“2-aminopyrimidine modulators of the histamine H4 receptor”
143/2008	Glaxo Group Limited, United Kingdom (Priority 14-2-07 GB)	“Novel antibodies”
144/2008	1.Mrs.Hamidia Abid 2.Miss Azra Yasmeen 3.Mr.arshad Hussain and 4.Mr.Javed Ali PCSIR, Labs. Peshawar, Pakistan	“Process for the preparation of instant rice kheer”
145/2008	Munawar Ahmed Malik Rawalpindi, Pakistan. Provisional	“Solar concrete brick”
146/2008	Munawar Ahmed Malik Rawalpindi, Pakistan. Provisional	“Stone mud block”
147/2008	Munawar Ahmed Malik Rawalpindi, Pakistan. Provisional	“Life time calendar”
148/2008	Munawar Ahmed Malik Rawalpindi, Pakistan. Provisional	“Concrete insulated block”

149/2008	Munawar Ahmed Malik Rawalpindi, Pakistan. Provisional	“Solar chips”
150/2008	Munawar Ahmed Malik Rawalpindi, Pakistan. Provisional	“Solar geyser cum solar cooker”
	<u>13-02-2008</u>	
151/2008	Harley Resources, Inc. Great Britain. (Priority 13-02-07 Spain)	“Connected structural panels for buildings”
152/2008	Mitsubishi Heavy Industries, Ltd. Japan. (Priority 10-07-07 Japan)	“Fluid mixing channel structure and mixing method”
153/2008	Pfizer Products Inc. U.S.A. (Priority 26-02-07 USA)	“Heterocyclic compounds useful in treating diseases and conditions”
154/2008	TransTech Pharma, Inc., U.S.A. (Priority 15-02-07 USA)	“Immunoglobulin fusion proteins and methods of making”
155/2008	1. Mrs.Zahra Yaqeen. 2. Dr. Atiq-ur-Rahman. 3. Dr. Zakir-ur-Rehman. 4. Mr.Muhammad Saleem P.C.S.I.R. Karachi.	“A process for the production of cough and flu granules”
156/2008	N.V. Organon. Netherlands. (Priority 22-02-07 Europe)	“Indole derivatives”
157/2008	Bristol-Myers Squibb Company. U.S.A.	“Hepatitis C virus inhibitors”
158/2008	Novartis AG. Switzerland. (Priority 15-02-07 USA)	“Combinations of therapeutic agents for treating cancer”
159/2008	Smithkline Beecham Corporation. USA. (Priority 16-02-07 USA)	“Cancer treatment method”

160/2008	<u>14-02-2008</u> Theravance, Inc. USA. (Priority 28-02-07 USA)	“Crystalline forms of an 8-azabicyclo[3.2.1.]octane compound”
161/2008	Tibotec Pharmaceuticals Ltd. Ireland. (Priority 16-02-07 Europe)	“1,1-Dioxo-1-thia-5,10-diazadibenzocycloheptenes useful as hepatitis C virus inhibitors”
162/2008	Argenta Discovery Ltd. United Kingdom. (Priority 15-02-07 GB)	“Compounds and their use II”
163/2008	Bilcare Limited . India. (Priority 21-02-07 India)	“A personalized healthcare management system”
164/2008	Furqan Khurshid. Lahore-Pakistan.	“Manual display screen”
165/2008	<u>15-02-2008</u> Unilever PLC. United Kingdom. (Priority 02-03-07 India)	“Tea composition”
166/2008	Sunesis Pharmaceuticals, Inc. USA. (Priority 15-02-07 USA)	“Carbon-linked tetrahydro-pyrazolo-pyridine modulators of cathepsins”
167/2008	Photint Venture Group Inc. Great Britain. (Priority 14-02-07 India)	“Banana codec”
168/2008	Photint Venture Group Inc. Great Britain. (Priority 14-02-07 India)	“Fuzzy protection”
169/2008	1. AstraZeneca AB. Sweden. 2. Medimmune Limited United Kingdom (Priority 15-02-07 USA)	“Binding members for IgE molecules”
170/2008	AstraZeneca AB. Sweden. 2. Medimmune Limited United Kingdom (Priority 21-02-07 USA)	“Compounds”

171/2008	Boehringer Ingelheim International GmbH. Germany.	“New compounds”
172/2008	SmithKline Beecham Corporation. USA. (Priority 19-02-07 USA)	“Compounds”
	<u>16-02-2008</u>	
173/2008	Bayer CropScience AG. Germany. (Priority 19-02-07 Europe)	“Herbicide combination”
174/2008	Bayer CropScience AG. Germany. (Priority 19-02-07 Japan)	“Mixed herbicidal compositions”
175/2008	Bayer HealthCare AG. Germany. (Priority 27-02-07 Germany)	“Substituted 4-aryl-1, 4-dihydro-1, 6-naphthyridine amides and their use”
176/2008	Pfizer Products Inc, USA (Priority 31-12-97 USA) Divisional	“Pharmaceutically acceptable salt of 5, 8, 14-triazatetraeyelo [10-3-1-02, 1104, 9] hexadeca-2(11), 3, 5, 7, 9,-Pentaena”
177/2008	1. Sephen Perrin Williams. 2. Cheng-chen Yeh. New Zealand.	“Boxing bag”
178/2008	Wyeth. USA. (Priority 16-02-07 USA)	“Sustained-release tablet formulations of piperazine-piperidine antagonists and agonists of the (5HT1A) receptor having enhanced intestinal dissolution”
179/2008	Oncotherapy Science, Inc. Japan. (Priority 21-02-07 USA)	“Peptide vaccines for cancers expressing tumor-associated antigens”
180/2008	Novartis AG. Switzerland. (Priority 19-02-07 Europe)	“Aryl carboxylic acid cyclohexyl amide derivatives”

APPLICATION ACCEPTED

Notice is hereby given that the person interested in opposing the grant of Patents to any of the applications referred to below at any time within four months from the date of this Gazette may give notice at the Patent Office on the prescribed Form P-7 of the Patents Rules 18(1) of 2003.

The six figures number shown in the right hand side are those given to applications on acceptance of the complete specification under which the specification will be printed and subsequent proceeding taken.


The figures shown within square brackets after the title of inventions indicate their classification index at acceptance.

Typed copies of the specification which are to open to public inspection can be supplied by the Patent Office on payment of the prescribed charges which may be ascertained on application to the office.

- | | | | |
|----------|---|---|--------|
| 391/1997 | Jassen Pharmaceutica
N.V.
Belgium | “Fast-dissolving galanthamine hydrobromide
tablet”

(A61K 9/20) | 139404 |
| | | The present invention is concerned with a fast-dissolving tablet for oral administration comprising as an active ingredient a therapeutically effective amount of galanthamine hydrobromide (1: 1) and a pharmaceutically acceptable carrier, characterized in that said carrier comprises a spray-dried mixture of lactose monohydrate and microcrystalline cellulose (75 : 25) as a diluent, and a disintegrant; and with a direct compression process of preparing such fast-dissolving tablets. | |
| 392/1997 | Janssen
Pharmaceutica N.V.
Belgium. | “Imidazol-5-yl)2-quinolone compound”

(CO7D 215/22) | 139405 |
| | | This invention comprises the novel compound of formula (I) | |



wherein the dotted line represents an optional bond; X is oxygen or sulfur; R1 is hydrogen, C1-12alkyl, Ar1, (Ar)2C1-6alkyl, quinolinylC1-6-alkyl, pyridylC1-6alkyl, hydroxyC1-6alkyl, C1-6alkyloxyC1-6alkyl, mono- or di(C1-6alkyl)aminoC1-6alkyl, aminoC1-6alkyl, or a radical of formula $-(Alk)_1-C(=O)R_9$, $-(Alk)_1S(O)-R_9$ or $-Alk_1-S(O)_2-R_9$; R2, R3 and R16 each independently are hydrogen, hydroxy, halo, cyano, C1-6alkyl, C1-6alkyloxy, hydroxyC1-6alkyloxy, C1-6alkyloxyC1-6alkyloxy, aminoC1-6alkyloxy, mono- or di(C1-6alkyl)aminoC1-6alkyloxy, (Ar)1 Ar2C1-6alkyl, Ar2oxy, Ar2C1-6alkyloxy, hydroxycarbonyl, C1-6alkyloxycarbonyl, trihalomethyl, trihalomethoxy, C2-6alkenyl; R4 and R5 each independently are hydrogen, halo, Ar1, C1-6alkyl, hydroxyC1-6alkyl, C1-6alkyloxyC1-6alkyl, C1-6alkyloxy, C1-6alkylthio, amino, hydroxycarbonyl, C1-6alkyloxycarbonyl, C1-6alkylS(O)C1-6alkyl or C1-6alkylS(O)2C1-6alkyl; R6 and R7 each independently are hydrogen, halo, cyano, C1-6alkyl, 4,4-dimethyl-oxazolyl, C1-6alkyloxy or Ar2oxy; (R)8 is hydrogen, C1-6alkyl, cyano, hydroxycarbonyl, C1-6alkyloxycarbonyl, C1-alkylcarbonylC1-6alkyl, cyanoC1-6alkyl, C1-6alkyloxycarbonylC1-6,alkyl, carboxyC1-6alkyl, hydroxyC1-6,alkyl, aminoC1-6alkyl, mono- or di(C1-6alkyl)aminoC1-6alkyl, imidazolyl, haloC1-6alkyl, C1-6alkyloxyC1-6alkyl, aminocarbonylC1-6alkyl, or a radical of formula $-O-R_{10}$, $-S-R_{10}$, $-N-R_{11}R_{12}$; R17 is hydrogen, halo, cyano, C1-6alkyl, C1-6alkyloxycarbonyl, Ar1; R18 is hydrogen, C1-6alkyl, C1-6alkyloxy or halo; R19 is hydrogen or C1-6alkyl having farnesyl transferase inhibiting activity; their preparation, compositions containing them and their use as a medicine.


393/1997 Janssen
Pharmaceutica N.V.
Belgium.

“Novel ester of 3-Hydroxy-piperidine-methanol
compound”

(CO7D 295/04)

139406

The present invention of compound of formula(I)



a stereochemically isomeric form thereof, an N-oxide form thereof, (R)¹ is C1-6alkyloxy, (C)²-6alkenyloxy or (C)²-6alkynyloxy; (R)² is hydrogen or (C)¹-6alkyloxy, or when taken together (R)¹ and (R)²

may form a bivalent radical of formula wherein in said bivalent radicals one or two hydrogen atoms may be substituted with (C)¹-6alkyl, (R)³ is hydrogen or halo; (R)⁴ is hydrogen or (C)¹-6alkyl; L is (C)³-6cycloalkyl, (C)⁵-6cycloalkanone, C²-6alkenyl optionally

substituted with aryl, or L is a radical of formula -A¹R-(R)⁵-, Alk-X-(R)⁶, -Alk-Y-C(=O)-(R)⁸, or -Alk-Y-C(=O)-(NR)¹⁰(R)¹¹ wherein each Alk is (C)¹-12alkanediyl; and (R)⁵ is

hydrogen, cyano, (C)¹-6alkylsulfonylamino, (C)³-6cycloalkyl, (C)⁵-6cycloalkanone, aryl, di(aryl)methyl or a heterocyclic ringsystem; (R)⁶ is hydrogen, (C)¹-6alkyl, hydroxy(C)¹-6alkyl, (C)³-6cycloalkyl, aryl or a heterocyclic ringsystem;

X is O, S, (SO)² or (NR)⁷; said (R)⁷ being hydrogen, (C)¹-6alkyl or aryl; (R)⁸ is hydrogen, (C)¹-6alkyl, (C)³-6cycloalkyl, aryl, aryl(C)¹-6alkyl, di(aryl)methyl, (C)¹-6alkyloxy or hydroxy; Y is (NR)⁹ or a direct bond; said (R)⁹ being hydrogen, (C)¹-6alkyl or aryl;

(R)¹⁰ and (R)¹¹ each independently are hydrogen, (C)¹-6alkyl, (C)³-6cycloalkyl, aryl or aryl(C)³-6alkyl, or (R)¹⁰ and (R)¹¹ combined with the nitrogen atom bearing (R)¹⁰ and (R)¹¹ may form a pyrrolidinyl or piperidinyl ring both being optionally substituted with (C)¹-6alkyl, amino or mono ordi(C)¹-6alkyl)amino, or said (R)¹⁰ and (R)¹¹ combined with the nitrogen bearing (R)¹⁰

and (R)11 may form a piperazinyl or 4-morpholinyl radical both being optionally substituted with (C)1-6alkyl. Processes for preparing said products, formulations comprising said products and their use as a medicine are disclosed, in particular for treating conditions which are related to impairment of gastric emptying.

127/1998 Bristol-Myers Squibb Company.
USA.

“Novel compound of Benzodioxole”

(CO7D 307/79)

139407

Novel of benzodioxole, benzofuran, 2,3-dihydrobenzofuran, and Benzodioxane are useful as melatonergic agents.


712/1998 Janssen Pharmaceutica N.V.
Belgium.

“2,4,4-Trisubstituted-1,3-dioxolane”


(CO7D 319/08)

139408

The present invention concerns novel compound of formula



a N-oxide form or a stereochemically isomeric form thereof, wherein n is zero, 1,2 or 3; X is Nor CH; each R1 independently is halo, nitro, cyano, amino, hydroxy, CI-4alkyl, CI-4alkyloxy or trifluoromethyl; R2 is hydrogen; C3-7alkenyl; C3-7alkynyl, aryl; C3-7Cycloalkyl; optionally substituted CI-6alkyl R3 and R4 each independently are hydrogen, CI-6alkyl, C3-7cycloalkyl or aryl; or R3 and R4 taken together form a bivalent radical -R3_R4- of formula



wherein R5a, R5b, R5c, R5d each independently are hydrogen, CI-6alkyl or aryl; and aryl is optionally substituted phenyl; as antifungals; their preparation, compositions containing them and their use as a medicines.


1039/1998 Pfizer Inc.
USA.

“(3-(((2-(3,5-dichloro-phenoxy)-ethyl)-(pyridine-3-sulfonyl) amino)-methyl)-phenoxy)-acetic acid”

(A61P 19/10)

139409

This invention relates to prostaglandin agonists, of the compound having the formula (1)



Pharmaceutical compositions containing such prostaglandin agonists. The prostaglandin agonists are useful for the treatment of bone disorders including osteoporosis.


821/1999 Wyeth Holdings
Corporation.
USA.

“Substituted 3-cyanoquinoline”

(CO7D 215/02)

139410

This invention provides compound of formula I, having the structure



Wherein R1, G1, G2, R4, Z, X, and n are defined herein, which are useful as antineoplastic agents and in the treatment of polycystic kidney disease.


1041/1999 Bristol-Myers Squibb
Company.
USA.

“3-Substituted-4-arylquinolin-2-one compound”

(CO7D 215/52, CO7D 453/04, A61K 31/47)

139411

The present invention provides novel 3-substituted-4-arylquinolin-2-one having the general formula



wherein R, R1, R2, R3, R4, R5, R6 and R7 are as defined herein, or a non-toxic pharmaceutically acceptable salt thereof which are modulators of the large conductance calcium-activated K⁺ channels and are useful in the treatment of disorders which are responsive to the opening of the potassium channels.

- | | | |
|----------|--|---|
| 80/2000 | Unilever Plc.
England. | <p>“A method for preparing a cold water infusing leaf tea”</p> <p>(A23F 3/34)</p> <p style="text-align: right;">139412</p> <p>A method for preparing a cold water infusing leaf tea. Green tea leaves are macerated, treated with tannase, fermented in the presence of hydrogen peroxide in an amount that is sufficient to activate endogenous peroxidases to oxidize gallic acid and other compounds that are liberated by the tannase treatment, and then dried. The final product is a black leaf tea that infuses in hot or cold water to give good flavour and colour.</p> |
| 119/2000 | American Cyanamid
Company.
USA. | <p>“A light extruded composition comprising agricultural compounds”</p> <p>(A01N 55/00)</p> <p style="text-align: right;">139413</p> <p>A light extruded composition which comprises at least one agricultural compound; a light, extrudable, ceramic carrier; and at least one surface active agent.</p> |
| 342/2000 | Smithkline Beecham
p.l.c.
England. | <p>“A 5-[4-[2-(N-methyl)-N-(2-pyridyl)amino]ethoxy]benzyl]thiazolidine-2,4-dione, hydrochloride dehydrate”</p> <p>(CO7D 285/18)</p> <p style="text-align: right;">139414</p> <p>5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione, hydrochloride dehydrate characterized in that it:</p> <p>(i) provides an X-ray powder diffraction</p> |

(XRPD) pattern containing peaks at 9.1, 12.0, 15.7, 16.3 and 19.8 2θ ; a pharmaceutical composition containing such a compound, and the use of such a compound in medicine.


1023/2000 Bristol-Myers Squibb Company.
USA.

“N-[5-[[[5-alkyl]-2-oxazolyl]methyl]thio]-2-thiazolyl]carboxamide inhibitor of cyclin dependent kinase”

(CO7D 263/32, CO7D 277/22)

139415

The present invention describes compounds of formula I:



The formula I compounds are protein kinase inhibitors and are useful in the treatment of proliferative diseases, for example, cancer, inflammation and arthritis. They may also be useful in the treatment of Alzheimer's disease, chemotherapy-induced alopecia, and cardiovascular disease.


1098/2000 Glaxo Group Limited.
Great Britain.

“Substituted thiazole”

(CO7D 277/10)

139416

A compound of formula (1) solvates and hydrolysable ester thereof



Wherein;

X1, represents O or S;

R¹ and R² independently represent H, halogen, -CH₃ and -OCH₃; n represents 1 or 2; X₂ represents NH, NCH₃ or O; One of Y and Z is N, and the other is or S;

R³ represents phenyl or pyridyl (wherein the N is in position 2 or 3) and is optionally substituted by one or more halogen, NO₂, NH₂, CF₃, OCF₃, OC[^] straight or branched alkyl, C[^] straight or branched alkyl, alkenyl or alkynyl with the provision that when R³ is pyridyl, the N is unsubstituted;

R⁴ represents CF₃ or CH₃


1164/2000 Bristol-Myers Squibb Company.
USA.

“Water soluble prodrugs of azole compound”

(A16K 31/663)

139417

Water-soluble prodrugs of triazole antifungal compounds having a secondary or tertiary hydroxy group are provided. More particularly, new water-soluble triazole antifungal compounds are provided having the general formula



wherein A is the non-hydroxy portion of a triazole antifungal compound of the type containing a secondary or tertiary hydroxyl group and R and (R)¹ are as defined in the specification.


170/2002 Bristol-Myers Squibb Pharma Company.
USA.

“A 4-(2-butylamino)-2,7-dimethyl-8-(2-methyl-6-methoxy-pyrid-3-yl)pyrazole-[1,5-A]-1,3,5-triazine compound,

(CO7D 487/04)

139418

Corticotropin releasing factor (CRF) antagonists of Formula (I):



and its use in treating anxiety, depression, and other psychiatric, neurological disorders as well as treatment of immunological, cardiovascular or heart-related diseases and colonic hypersensitivity associated with psychopathological disturbance and stress.

177/2002 Wyeth
USA.

“A pharmaceutical composition comprising conjugated estrogen and medroxyprogesterone acetate”

(A61K 31/565)

139419

This invention relates to pharmaceutical compositions for providing hormone replacement therapy in perimenopausal, menopausal, and postmenopausal women through the continuous administration of combinations of conjugated estrogens and medroxyprogesterone acetate.


703/2002 E.I. Du Pont De
Nemours and
Company.
USA.

“A substituted Anthranilamide for controlling invertebrate pests”

(AO1N 37/32)

139420

This invention provides compound of Formula I, and N-oxides



wherein A, B, R1 through R5, R7 through R9, X and Y are as defined in the disclosure.

Also disclosed are methods for controlling an

invertebrate pest comprising contacting the invertebrate pest or its environment with a biologically effective amount of a compound of Formula I. Also disclosed are compositions for controlling an invertebrate pest comprising the compounds of Formula.


1016/2002 Warner-Lambert
Company.
USA.

“Cyclic amino acid”

(CO7D 295/04)

139421

The present invention provides compound of Formula (I):



Wherein A, B, C, G, and W1 have any of the values defined in the specification, that are useful to treat thrombotic disorders. Also disclosed are pharmaceutical compositions comprising one or compound of Formula I,


431/2003 Bristol-Myers Squibb
Company.
USA.

“Pyrazolo-Pyrimidine Aniline Compound”

(CO7D 471/02)

139422

Compound having the formula(I), where all substituents are as defined herein,



are useful as kinase inhibitors.

1120/2005 Unilever PLC.
United Kingdom

“A process for making bar composition”

(C11D 13/00, C11D 9/48)

139423


The invention relates to novel method of incorporating free fatty acid into soap-based bars to

minimize or eliminate efflorescence and to compositions made by the process.

1148/2006 Bristol-Myers Squibb Company, USA. "Pyrazolo-pyrimidine aniline compound" (CO7D 471/02)

139424

Compound having the formula (I), where all substituents are as defined herein,




prodrugs, and solvates thereof, are useful as kinase inhibitors.

1332/2006 Bristol-Myers Squibb Company, USA. "A nontoxic pharmaceutically acceptable salt of 3-substituted-4-arylquinolin-2-one compound" (CO7D 215/52, CO7D 453/04, A61K 31/47)

139425

The present invention provides novel 3-substituted - 4-arylquinolin-2-one compound having the general formula.



Wherein R, R₁, R₂, R₃, R₄, R₅, R₆, and R₇ are as defined herein, which are modulators of the large conductance calcium-activated K⁺ channels and are useful in the treatment of disorders which are responsive to the opening of the potassium channels.

(Mrs. Yasmeen Abbasi)
Controller of Patents
Tel: 9215488